APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Influenza Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Multivalent Influenza Vaccines Industry Growth and Trends Forecast to 2032

29 December 2025119 pages

Choose your research edition.

Industry ResearchMultivalent Influenza Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Influenza Vaccines Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Multivalent Influenza Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Influenza Vaccines Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Influenza Vaccines Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Multivalent Influenza Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multivalent Influenza Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multivalent Influenza Vaccines include CSL, KM Biologics, Viatris, AstraZeneca, Bcht Biotechnology, Sinovac, Aleph Biomedical, GSK and ADIMMUNE Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Multivalent Influenza Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Multivalent Influenza Vaccines market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Multivalent Influenza Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Multivalent Influenza Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Multivalent Influenza Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Multivalent Influenza Vaccines Market by Company

CSL

KM Biologics

Viatris

AstraZeneca

Bcht Biotechnology

Sinovac

Aleph Biomedical

GSK

ADIMMUNE Corporation

Hualan Bio

Jiangsu GDK

Sanofi

Shanghai Institute of Biological Products

Wuhan Institute of Biological Products

Changchun Institute of Biological

Zhongyianke Biotech

Multivalent Influenza Vaccines Segment by Type

Quadrivalent Inactivated Influenza Vaccine (IIV4)

Trivalent Inactivated Influenza Vaccine (IIV3)

Trivalent Live Attenuated Vaccine (LAIV3)

Multivalent Influenza Vaccines Segment by Application

6 Months to 3 Years

Above 3 Years

Multivalent Influenza Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Influenza Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Influenza Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Influenza Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multivalent Influenza Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Multivalent Influenza Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Quadrivalent Inactivated Influenza Vaccine (IIV4) Table 2. Major Company of Trivalent Inactivated Influenza Vaccine (IIV3) Table 3. Major Company of Trivalent Live Attenuated Vaccine (LAIV3) Table 4. Global Multivalent Influenza Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 6. Global Multivalent Influenza Vaccines Sales Market Share in Volume by Type (2021-2026) Table 7. Global Multivalent Influenza Vaccines Sales by Type (2021-2026) & (US$ Million) Table 8. Global Multivalent Influenza Vaccines Sales Market Share in Value by Type (2021-2026) Table 9. Global Multivalent Influenza Vaccines Price by Type (2021-2026) & (US$/Unit) Table 10. Global Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 11. Global Multivalent Influenza Vaccines Sales Market Share in Volume by Type (2027-2032) Table 12. Global Multivalent Influenza Vaccines Sales by Type (2027-2032) & (US$ Million) Table 13. Global Multivalent Influenza Vaccines Sales Market Share in Value by Type (2027-2032) Table 14. Global Multivalent Influenza Vaccines Price by Type (2027-2032) & (US$/Unit) Table 15. North America Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 16. North America Multivalent Influenza Vaccines Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 18. Europe Multivalent Influenza Vaccines Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Multivalent Influenza Vaccines Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 22. Latin America Multivalent Influenza Vaccines Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Multivalent Influenza Vaccines Sales by Type (2021-2026) & (US$ Million) Table 25. Multivalent Influenza Vaccines Industry Trends Table 26. Multivalent Influenza Vaccines Industry Drivers Table 27. Multivalent Influenza Vaccines Industry Opportunities and Challenges Table 28. Multivalent Influenza Vaccines Industry Restraints Table 29. Global Multivalent Influenza Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Multivalent Influenza Vaccines Revenue Market Share by Company (2021-2026) Table 31. Global Multivalent Influenza Vaccines Sales by Company (2021-2026) & (K Units) Table 32. Global Multivalent Influenza Vaccines Sales Share by Company (2021-2026) Table 33. Global Multivalent Influenza Vaccines Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Multivalent Influenza Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Multivalent Influenza Vaccines Major Company Production Sites and Headquarters Table 36. Global Multivalent Influenza Vaccines Company, Product Type & Application Table 37. Global Multivalent Influenza Vaccines Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Multivalent Influenza Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Multivalent Influenza Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Multivalent Influenza Vaccines Sales by Region (2021-2026) & (K Units) Table 42. Global Multivalent Influenza Vaccines Sales Market Share in Volume by Region (2021-2026) Table 43. Global Multivalent Influenza Vaccines Sales by Region (2021-2026) & (US$ Million) Table 44. Global Multivalent Influenza Vaccines Sales Market Share in Value by Region (2021-2026) Table 45. Global Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Multivalent Influenza Vaccines Sales by Region (2027-2032) & (K Units) Table 47. Global Multivalent Influenza Vaccines Sales Market Share in Volume by Region (2027-2032) Table 48. Global Multivalent Influenza Vaccines Sales by Region (2027-2032) & (US$ Million) Table 49. Global Multivalent Influenza Vaccines Sales Market Share in Value by Region (2027-2032) Table 50. Global Multivalent Influenza Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Multivalent Influenza Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 53. Global Multivalent Influenza Vaccines Sales Market Share in Volume by Application (2021-2026) Table 54. Global Multivalent Influenza Vaccines Sales by Application (2021-2026) & (US$ Million) Table 55. Global Multivalent Influenza Vaccines Sales Market Share in Value by Application (2021-2026) Table 56. Global Multivalent Influenza Vaccines Price by Application (2021-2026) & (US$/Unit) Table 57. Global Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 58. Global Multivalent Influenza Vaccines Sales Market Share in Volume by Application (2027-2032) Table 59. Global Multivalent Influenza Vaccines Sales by Application (2027-2032) & (US$ Million) Table 60. Global Multivalent Influenza Vaccines Sales Market Share in Value by Application (2027-2032) Table 61. Global Multivalent Influenza Vaccines Price by Application (2027-2032) & (US$/Unit) Table 62. North America Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 63. North America Multivalent Influenza Vaccines Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 65. Europe Multivalent Influenza Vaccines Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Multivalent Influenza Vaccines Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 69. Latin America Multivalent Influenza Vaccines Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Multivalent Influenza Vaccines Sales by Application (2021-2026) & (US$ Million) Table 72. CSL Company Information Table 73. CSL Business Overview Table 74. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. CSL Multivalent Influenza Vaccines Product Portfolio Table 76. CSL Recent Development Table 77. KM Biologics Company Information Table 78. KM Biologics Business Overview Table 79. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. KM Biologics Multivalent Influenza Vaccines Product Portfolio Table 81. KM Biologics Recent Development Table 82. Viatris Company Information Table 83. Viatris Business Overview Table 84. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Viatris Multivalent Influenza Vaccines Product Portfolio Table 86. Viatris Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. AstraZeneca Multivalent Influenza Vaccines Product Portfolio Table 91. AstraZeneca Recent Development Table 92. Bcht Biotechnology Company Information Table 93. Bcht Biotechnology Business Overview Table 94. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio Table 96. Bcht Biotechnology Recent Development Table 97. Sinovac Company Information Table 98. Sinovac Business Overview Table 99. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Sinovac Multivalent Influenza Vaccines Product Portfolio Table 101. Sinovac Recent Development Table 102. Aleph Biomedical Company Information Table 103. Aleph Biomedical Business Overview Table 104. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio Table 106. Aleph Biomedical Recent Development Table 107. GSK Company Information Table 108. GSK Business Overview Table 109. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. GSK Multivalent Influenza Vaccines Product Portfolio Table 111. GSK Recent Development Table 112. ADIMMUNE Corporation Company Information Table 113. ADIMMUNE Corporation Business Overview Table 114. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio Table 116. ADIMMUNE Corporation Recent Development Table 117. Hualan Bio Company Information Table 118. Hualan Bio Business Overview Table 119. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Hualan Bio Multivalent Influenza Vaccines Product Portfolio Table 121. Hualan Bio Recent Development Table 122. Jiangsu GDK Company Information Table 123. Jiangsu GDK Business Overview Table 124. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio Table 126. Jiangsu GDK Recent Development Table 127. Sanofi Company Information Table 128. Sanofi Business Overview Table 129. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Sanofi Multivalent Influenza Vaccines Product Portfolio Table 131. Sanofi Recent Development Table 132. Shanghai Institute of Biological Products Company Information Table 133. Shanghai Institute of Biological Products Business Overview Table 134. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 136. Shanghai Institute of Biological Products Recent Development Table 137. Wuhan Institute of Biological Products Company Information Table 138. Wuhan Institute of Biological Products Business Overview Table 139. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 141. Wuhan Institute of Biological Products Recent Development Table 142. Changchun Institute of Biological Company Information Table 143. Changchun Institute of Biological Business Overview Table 144. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio Table 146. Changchun Institute of Biological Recent Development Table 147. Zhongyianke Biotech Company Information Table 148. Zhongyianke Biotech Business Overview Table 149. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio Table 151. Zhongyianke Biotech Recent Development Table 152. North America Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 153. North America Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 154. North America Multivalent Influenza Vaccines Sales Market Share by Country (2021-2026) Table 155. North America Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 156. North America Multivalent Influenza Vaccines Sales Market Share Forecast by Country (2027-2032) Table 157. North America Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. North America Multivalent Influenza Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 159. North America Multivalent Influenza Vaccines Market Share by Country (2021-2026) Table 160. North America Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. North America Multivalent Influenza Vaccines Market Share Forecast by Country (2027-2032) Table 162. Europe Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 163. Europe Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 164. Europe Multivalent Influenza Vaccines Sales Market Share by Country (2021-2026) Table 165. Europe Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 166. Europe Multivalent Influenza Vaccines Sales Market Share Forecast by Country (2027-2032) Table 167. Europe Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Europe Multivalent Influenza Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 169. Europe Multivalent Influenza Vaccines Market Share by Country (2021-2026) Table 170. Europe Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Europe Multivalent Influenza Vaccines Market Share Forecast by Country (2027-2032) Table 172. Asia-Pacific Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 173. Asia-Pacific Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 174. Asia-Pacific Multivalent Influenza Vaccines Sales Market Share by Country (2021-2026) Table 175. Asia-Pacific Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 176. Asia-Pacific Multivalent Influenza Vaccines Sales Market Share Forecast by Country (2027-2032) Table 177. Asia-Pacific Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. Asia-Pacific Multivalent Influenza Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 179. Asia-Pacific Multivalent Influenza Vaccines Market Share by Country (2021-2026) Table 180. Asia-Pacific Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. Asia-Pacific Multivalent Influenza Vaccines Market Share Forecast by Country (2027-2032) Table 182. Latin America Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 183. Latin America Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 184. Latin America Multivalent Influenza Vaccines Sales Market Share by Country (2021-2026) Table 185. Latin America Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 186. Latin America Multivalent Influenza Vaccines Sales Market Share Forecast by Country (2027-2032) Table 187. Latin America Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. Latin America Multivalent Influenza Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 189. Latin America Multivalent Influenza Vaccines Market Share by Country (2021-2026) Table 190. Latin America Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. Latin America Multivalent Influenza Vaccines Market Share Forecast by Country (2027-2032) Table 192. Middle East and Africa Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 193. Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 194. Middle East and Africa Multivalent Influenza Vaccines Sales Market Share by Country (2021-2026) Table 195. Middle East and Africa Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032) & (K Units) Table 196. Middle East and Africa Multivalent Influenza Vaccines Sales Market Share Forecast by Country (2027-2032) Table 197. Middle East and Africa Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 198. Middle East and Africa Multivalent Influenza Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 199. Middle East and Africa Multivalent Influenza Vaccines Market Share by Country (2021-2026) Table 200. Middle East and Africa Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 201. Middle East and Africa Multivalent Influenza Vaccines Market Share Forecast by Country (2027-2032) Table 202. Key Raw Materials Table 203. Raw Materials Key Suppliers Table 204. Multivalent Influenza Vaccines Distributors List Table 205. Multivalent Influenza Vaccines Customers List Table 206. Research Programs/Design for This Report Table 207. Authors List of This Report Table 208. Secondary Sources Table 209. Primary Sources List of Figures Figure 1. Multivalent Influenza Vaccines Image Figure 2. Global Multivalent Influenza Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multivalent Influenza Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Multivalent Influenza Vaccines Sales (2021-2032) & (K Units) Figure 5. Quadrivalent Inactivated Influenza Vaccine (IIV4) Image Figure 6. Global Quadrivalent Inactivated Influenza Vaccine (IIV4) Sales YoY Growth (2021-2032) & (K Units) Figure 7. Trivalent Inactivated Influenza Vaccine (IIV3) Image Figure 8. Global Trivalent Inactivated Influenza Vaccine (IIV3) Sales YoY Growth (2021-2032) & (K Units) Figure 9. Trivalent Live Attenuated Vaccine (LAIV3) Image Figure 10. Global Trivalent Live Attenuated Vaccine (LAIV3) Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Multivalent Influenza Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Multivalent Influenza Vaccines Market Share by Type 2025 VS 2032 Figure 13. North America Multivalent Influenza Vaccines Sales Market Share in Volume by Type in 2025 Figure 14. North America Multivalent Influenza Vaccines Sales Market Share in Value by Type in 2025 Figure 15. Europe Multivalent Influenza Vaccines Sales Market Share in Volume by Type in 2025 Figure 16. Europe Multivalent Influenza Vaccines Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Multivalent Influenza Vaccines Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Multivalent Influenza Vaccines Sales Market Share in Value by Type in 2025 Figure 19. Latin America Multivalent Influenza Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Multivalent Influenza Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Multivalent Influenza Vaccines Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Multivalent Influenza Vaccines Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Multivalent Influenza Vaccines Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. 6 Months to 3 Years Image Figure 26. Global 6 Months to 3 Years Sales YoY Growth (2021-2032) & (K Units) Figure 27. Above 3 Years Image Figure 28. Global Above 3 Years Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Multivalent Influenza Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Multivalent Influenza Vaccines Market Share by Application 2025 VS 2032 Figure 31. North America Multivalent Influenza Vaccines Sales Market Share in Volume by Application in 2025 Figure 32. North America Multivalent Influenza Vaccines Sales Market Share in Value by Application in 2025 Figure 33. Europe Multivalent Influenza Vaccines Sales Market Share in Volume by Application in 2025 Figure 34. Europe Multivalent Influenza Vaccines Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Multivalent Influenza Vaccines Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Multivalent Influenza Vaccines Sales Market Share in Value by Application in 2025 Figure 37. Latin America Multivalent Influenza Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Multivalent Influenza Vaccines Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Multivalent Influenza Vaccines Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Multivalent Influenza Vaccines Sales Market Share in Value by Application in 2025 Figure 41. North America Multivalent Influenza Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Multivalent Influenza Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Multivalent Influenza Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Multivalent Influenza Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Multivalent Influenza Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Multivalent Influenza Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Multivalent Influenza Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Multivalent Influenza Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Multivalent Influenza Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Multivalent Influenza Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Multivalent Influenza Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Multivalent Influenza Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Multivalent Influenza Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Multivalent Influenza Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Multivalent Influenza Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Multivalent Influenza Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Multivalent Influenza Vaccines Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Multivalent Influenza Vaccines Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Quadrivalent Inactivated Influenza Vaccine (IIV4)
  • Trivalent Inactivated Influenza Vaccine (IIV3)
  • Trivalent Live Attenuated Vaccine (LAIV3)
Applications
  • 6 Months to 3 Years
  • Above 3 Years
Companies covered
  • CSL
  • KM Biologics
  • Viatris
  • AstraZeneca
  • Bcht Biotechnology
  • Sinovac
  • Aleph Biomedical
  • GSK
  • ADIMMUNE Corporation
  • Hualan Bio
  • Jiangsu GDK
  • Sanofi
  • Shanghai Institute of Biological Products
  • Wuhan Institute of Biological Products
  • Changchun Institute of Biological
  • Zhongyianke Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multivalent Influenza Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Multivalent Influenza Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Multivalent Influenza Vaccines Market by Type
  6. 1.3.1 Quadrivalent Inactivated Influenza Vaccine (IIV4)
  7. 1.3.2 Trivalent Inactivated Influenza Vaccine (IIV3)
  8. 1.3.3 Trivalent Live Attenuated Vaccine (LAIV3)
  9. 1.4 Global Multivalent Influenza Vaccines Market Size by Type
  10. 1.4.1 Global Multivalent Influenza Vaccines Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Multivalent Influenza Vaccines Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Multivalent Influenza Vaccines Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Multivalent Influenza Vaccines Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Multivalent Influenza Vaccines Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Multivalent Influenza Vaccines Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Multivalent Influenza Vaccines Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Multivalent Influenza Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Multivalent Influenza Vaccines Industry Trends
  2. 2.2 Multivalent Influenza Vaccines Industry Drivers
  3. 2.3 Multivalent Influenza Vaccines Industry Opportunities and Challenges
  4. 2.4 Multivalent Influenza Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Multivalent Influenza Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by Multivalent Influenza Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by Multivalent Influenza Vaccines Price (2021-2026)
  4. 3.4 Global Multivalent Influenza Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multivalent Influenza Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global Multivalent Influenza Vaccines Company, Product Type & Application
  7. 3.7 Global Multivalent Influenza Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multivalent Influenza Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multivalent Influenza Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multivalent Influenza Vaccines Tier 1, Tier 2, and Tier 3
4 Multivalent Influenza Vaccines Regional Status and Outlook
  1. 4.1 Global Multivalent Influenza Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Multivalent Influenza Vaccines Historic Market Size by Region
  3. 4.2.1 Global Multivalent Influenza Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Multivalent Influenza Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Multivalent Influenza Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Multivalent Influenza Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global Multivalent Influenza Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Multivalent Influenza Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Multivalent Influenza Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Multivalent Influenza Vaccines by Application
  1. 5.1 Multivalent Influenza Vaccines Market by Application
  2. 5.1.1 6 Months to 3 Years
  3. 5.1.2 Above 3 Years
  4. 5.2 Global Multivalent Influenza Vaccines Market Size by Application
  5. 5.2.1 Global Multivalent Influenza Vaccines Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Multivalent Influenza Vaccines Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Multivalent Influenza Vaccines Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Multivalent Influenza Vaccines Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Multivalent Influenza Vaccines Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Multivalent Influenza Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Multivalent Influenza Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Multivalent Influenza Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 CSL
  2. 6.1.1 CSL Company Information
  3. 6.1.2 CSL Business Overview
  4. 6.1.3 CSL Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 CSL Multivalent Influenza Vaccines Product Portfolio
  6. 6.1.5 CSL Recent Developments
  7. 6.2 KM Biologics
  8. 6.2.1 KM Biologics Company Information
  9. 6.2.2 KM Biologics Business Overview
  10. 6.2.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 KM Biologics Multivalent Influenza Vaccines Product Portfolio
  12. 6.2.5 KM Biologics Recent Developments
  13. 6.3 Viatris
  14. 6.3.1 Viatris Company Information
  15. 6.3.2 Viatris Business Overview
  16. 6.3.3 Viatris Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Viatris Multivalent Influenza Vaccines Product Portfolio
  18. 6.3.5 Viatris Recent Developments
  19. 6.4 AstraZeneca
  20. 6.4.1 AstraZeneca Company Information
  21. 6.4.2 AstraZeneca Business Overview
  22. 6.4.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 AstraZeneca Multivalent Influenza Vaccines Product Portfolio
  24. 6.4.5 AstraZeneca Recent Developments
  25. 6.5 Bcht Biotechnology
  26. 6.5.1 Bcht Biotechnology Company Information
  27. 6.5.2 Bcht Biotechnology Business Overview
  28. 6.5.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio
  30. 6.5.5 Bcht Biotechnology Recent Developments
  31. 6.6 Sinovac
  32. 6.6.1 Sinovac Company Information
  33. 6.6.2 Sinovac Business Overview
  34. 6.6.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sinovac Multivalent Influenza Vaccines Product Portfolio
  36. 6.6.5 Sinovac Recent Developments
  37. 6.7 Aleph Biomedical
  38. 6.7.1 Aleph Biomedical Company Information
  39. 6.7.2 Aleph Biomedical Business Overview
  40. 6.7.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio
  42. 6.7.5 Aleph Biomedical Recent Developments
  43. 6.8 GSK
  44. 6.8.1 GSK Company Information
  45. 6.8.2 GSK Business Overview
  46. 6.8.3 GSK Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GSK Multivalent Influenza Vaccines Product Portfolio
  48. 6.8.5 GSK Recent Developments
  49. 6.9 ADIMMUNE Corporation
  50. 6.9.1 ADIMMUNE Corporation Company Information
  51. 6.9.2 ADIMMUNE Corporation Business Overview
  52. 6.9.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio
  54. 6.9.5 ADIMMUNE Corporation Recent Developments
  55. 6.10 Hualan Bio
  56. 6.10.1 Hualan Bio Company Information
  57. 6.10.2 Hualan Bio Business Overview
  58. 6.10.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hualan Bio Multivalent Influenza Vaccines Product Portfolio
  60. 6.10.5 Hualan Bio Recent Developments
  61. 6.11 Jiangsu GDK
  62. 6.11.1 Jiangsu GDK Company Information
  63. 6.11.2 Jiangsu GDK Business Overview
  64. 6.11.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio
  66. 6.11.5 Jiangsu GDK Recent Developments
  67. 6.12 Sanofi
  68. 6.12.1 Sanofi Company Information
  69. 6.12.2 Sanofi Business Overview
  70. 6.12.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Sanofi Multivalent Influenza Vaccines Product Portfolio
  72. 6.12.5 Sanofi Recent Developments
  73. 6.13 Shanghai Institute of Biological Products
  74. 6.13.1 Shanghai Institute of Biological Products Company Information
  75. 6.13.2 Shanghai Institute of Biological Products Business Overview
  76. 6.13.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  78. 6.13.5 Shanghai Institute of Biological Products Recent Developments
  79. 6.14 Wuhan Institute of Biological Products
  80. 6.14.1 Wuhan Institute of Biological Products Company Information
  81. 6.14.2 Wuhan Institute of Biological Products Business Overview
  82. 6.14.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  84. 6.14.5 Wuhan Institute of Biological Products Recent Developments
  85. 6.15 Changchun Institute of Biological
  86. 6.15.1 Changchun Institute of Biological Company Information
  87. 6.15.2 Changchun Institute of Biological Business Overview
  88. 6.15.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio
  90. 6.15.5 Changchun Institute of Biological Recent Developments
  91. 6.16 Zhongyianke Biotech
  92. 6.16.1 Zhongyianke Biotech Company Information
  93. 6.16.2 Zhongyianke Biotech Business Overview
  94. 6.16.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio
  96. 6.16.5 Zhongyianke Biotech Recent Developments
7 North America by Country
  1. 7.1 North America Multivalent Influenza Vaccines Sales by Country
  2. 7.1.1 North America Multivalent Influenza Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Multivalent Influenza Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America Multivalent Influenza Vaccines Market Size by Country
  6. 7.2.1 North America Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Multivalent Influenza Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Multivalent Influenza Vaccines Sales by Country
  2. 8.1.1 Europe Multivalent Influenza Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Multivalent Influenza Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Multivalent Influenza Vaccines Market Size by Country
  6. 8.2.1 Europe Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Multivalent Influenza Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Multivalent Influenza Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific Multivalent Influenza Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Multivalent Influenza Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Multivalent Influenza Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Multivalent Influenza Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Multivalent Influenza Vaccines Sales by Country
  2. 10.1.1 South America Multivalent Influenza Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Multivalent Influenza Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America Multivalent Influenza Vaccines Market Size by Country
  6. 10.2.1 South America Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Multivalent Influenza Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Multivalent Influenza Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa Multivalent Influenza Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Multivalent Influenza Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Multivalent Influenza Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa Multivalent Influenza Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Multivalent Influenza Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Multivalent Influenza Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Multivalent Influenza Vaccines Value Chain Analysis
  2. 12.1.1 Multivalent Influenza Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Multivalent Influenza Vaccines Production Mode & Process
  7. 12.2 Multivalent Influenza Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Multivalent Influenza Vaccines Distributors
  10. 12.2.3 Multivalent Influenza Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst